Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 3–7% of patients with non-small cell lung cancer (NSCLC) and are more common among patients with a never/light smoking history, adenocarcinoma histology, a younger age, female gender and in patient with tumors with a wild-type status for the EGFR and KRAS genes (1).